Immunic, Inc

1200 Avenue of the Americas, Suite 200
New York, NY 10036, USA

Phone: +49 89 2080 477 00
Email: info@imux.com

Immunic AG

Lochhamer Schlag 21
82166 Gräfelfing, Germany

Phone: +49 89 2080 477 00
Email: info@imux.com

ante

May 17, 2021

BEAT-COV Endorses Initiative of the German Government for EUR 300 Million Funding Program for Late-Stage COVID-19 Therapies (in German Only)

BEAT-COV begrüßt Initiative des Bundes für 300 Millionen Euro Förderprogramm für versorgungsnahe...

Read More
May 6, 2021

Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity

– EMPhASISCohort 2Interim Analysis Confirmed 30 mg Dose of IMU-838 as Most...

Read More
April 13, 2021

Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April

NEW YORK, April 13, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
March 31, 2021

Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838

NEW YORK and PLANEGG-MARTINSRIED, Germany, March 31, 2021 – Immunic, Inc. (Nasdaq: IMUX),a...

Read More
March 2, 2021

Immunic, Inc. to Participate in Industry and Investor Conferences in March

NEW YORK, March 2, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
February 26, 2021

Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity

– Phase 3 Program of IMU-838 in Relapsing-Remitting Multiple Sclerosis Expected to...

Read More
January 8, 2021

Development of Innovative COVID-19 Therapies Needs Additional Public Funding to Help Patients in the Short-Term (in German Only)

Entwicklung innovativer COVID-19-Medikamente bedarf weitergehender öffentlicher Förderung, um Patienten schnell zu helfen...

Read More